Literature DB >> 12435434

Hallucinogens and Drosophila: linking serotonin receptor activation to behavior.

C D Nichols1, J Ronesi, W Pratt, E Sanders-Bush.   

Abstract

The similarity of mode of action, behavior, and gene response between Drosophila melanogaster and mammalian systems, combined with the power of genetics, have recently made the fly an attractive system to study underlying mechanisms of drug abuse, addiction, and mental disorders. The present studies define the behavioral and molecular effects of the powerful hallucinogen lysergic acid diethylamide in Drosophila. Pharmacological activation of serotonin receptors in the fly by lysergic acid diethylamide induces behaviors not unlike those observed in mammalian systems. These include alterations in visual processing abilities, reduced locomotor activity, and altered gene expression within the brain. Many of these effects are due to activation of the same serotonin receptor subtypes that are thought to be the primary mediators of hallucinogenic drug effects in humans as well as the acute symptoms of schizophrenia.We suggest that Drosophila can be used as a genetically tractable model system to define the molecular events leading from serotonin receptor activation to behavior, possibly revealing new targets for hallucinogenic agents and for the treatment of neuropsychiatric disorders such as schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12435434     DOI: 10.1016/s0306-4522(02)00354-8

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  13 in total

1.  Bedraggled, a putative transporter, influences the tissue polarity complex during the R3/R4 fate decision in the Drosophila eye.

Authors:  Amy S Rawls; Sarah A Schultz; Robi D Mitra; Tanya Wolff
Journal:  Genetics       Date:  2007-09       Impact factor: 4.562

2.  Visual mutations reveal opposing effects of illumination on arousal in Drosophila.

Authors:  Yuzhong Cheng; Howard A Nash
Journal:  Genetics       Date:  2008-04       Impact factor: 4.562

3.  Characterization of the 5-HT1A receptor of the honeybee (Apis mellifera) and involvement of serotonin in phototactic behavior.

Authors:  Markus Thamm; Sabine Balfanz; Ricarda Scheiner; Arnd Baumann; Wolfgang Blenau
Journal:  Cell Mol Life Sci       Date:  2010-03-28       Impact factor: 9.261

4.  DREADDs in Drosophila: a pharmacogenetic approach for controlling behavior, neuronal signaling, and physiology in the fly.

Authors:  Jaime Becnel; Oralee Johnson; Zana R Majeed; Vi Tran; Bangning Yu; Bryan L Roth; Robin L Cooper; Edmund K Kerut; Charles D Nichols
Journal:  Cell Rep       Date:  2013-09-05       Impact factor: 9.423

5.  Serotonin receptor activity is necessary for olfactory learning and memory in Drosophila melanogaster.

Authors:  O Johnson; J Becnel; C D Nichols
Journal:  Neuroscience       Date:  2011-06-25       Impact factor: 3.590

Review 6.  Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds.

Authors:  Nikhil Neelkantan; Alina Mikhaylova; Adam Michael Stewart; Raymond Arnold; Visar Gjeloshi; Divya Kondaveeti; Manoj K Poudel; Allan V Kalueff
Journal:  ACS Chem Neurosci       Date:  2013-08-06       Impact factor: 4.418

Review 7.  Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery.

Authors:  Udai Bhan Pandey; Charles D Nichols
Journal:  Pharmacol Rev       Date:  2011-03-17       Impact factor: 25.468

8.  Serotonin 5-HT(2) and 5-HT(1A)-like receptors differentially modulate aggressive behaviors in Drosophila melanogaster.

Authors:  O Johnson; J Becnel; C D Nichols
Journal:  Neuroscience       Date:  2008-11-07       Impact factor: 3.590

Review 9.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

10.  An Argument for Amphetamine-Induced Hallucinations in an Invertebrate.

Authors:  Anne H Lee; Cindy L Brandon; Jean Wang; William N Frost
Journal:  Front Physiol       Date:  2018-06-25       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.